Headquartered in Westlake Village, CA Fiscal year ends December NASDAQ: TTRX turntherapeutics.com
Turn Therapeutics Inc. (Nasdaq: TTRX) is a pre-revenue, clinical-stage biotechnology company developing targeted, non-systemic topical therapies for inflammatory and infectious skin diseases.
Its lead candidate, GX-03, is a proprietary topical formulation. It is built on the same core formula as the company's prior FDA-cleared products and is designed to combine anti-inflammatory activity with bacterial membrane-disrupting properties.
GX-03's development programs:
- **Atopic dermatitis:** A Phase 2b trial in 120–136 patients with severe itch is ongoing, following a completed 50-patient Stage 1/Phase 2a trial. Topline Phase 2b results are expected in Q1 2027.
- **Hidradenitis suppurativa:** An approximately 80-patient Phase 2a trial is planned, with enrollment expected to begin in Q1 2027.
- **Onychomycosis (nail fungus):** Supported by animal nail-penetration data and investigator-sponsored human evidence.
The company funds operations through equity and financing facilities. Former CDC Director Robert R. Redfield, M.D., serves as Chief Scientific Officer, and Stephen M. Hahn, M.D., serves as Executive Clinical and Regulatory Lead. Updated
Pre-Market Stock Futures: The futures are trading lower as we begin the final trading week of 2025, albeit a holiday-shortened one once again. The major indices all finished the session modestly lower…
Turn Therapeutics Inc. (Nasdaq: TTRX) is a pre-revenue, clinical-stage biotechnology company developing targeted, non-systemic topical therapies for inflammatory and infectious skin diseases. Its lead candidate, GX-03, is a proprietary topical formulation.
The Wall Street consensus 12-month price target for TTRX is $25.00.
